Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.42 |
| ▸ | BRD4 | O60885 | 13/20 | 0.41 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4014501 | 0.78 | BRD4 (0.38) | MAPK14BRD4NPBWR1MCHR1MAPK8 | |
| SCHEMBL14019141 | 0.78 | BRD4 (0.39) | BRD4 | |
| SCHEMBL5202525 | 0.69 | MAPK14 (0.45) | MAPK14BRD4TRPA1 | |
| SCHEMBL10456772 | 0.67 | TRPA1 (0.56) | TRPA1 | |
| SCHEMBL13239748 | 0.67 | MAPK14 (0.57) | MAPK14MAPK8TRPA1 | |
| SCHEMBL29537119 | 0.67 | MAPK14 (0.57) | MAPK14MAPK8TRPA1 | |
| SCHEMBL22139066 | 0.67 | MAPK14 (0.60) | MAPK14MAPK8TRPA1 | |
| SCHEMBL14266291 | 0.66 | MAPK14 (0.56) | MAPK14BRD4MAPK8TRPA1 | |
| SCHEMBL16738717 | 0.66 | BRD4 (0.53) | MAPK14BRD4MAPK8 | |
| SCHEMBL24099148 | 0.64 | PARP1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPKAPK2, MAPK1, MAP3K2 | MAPK14 33/4885BRD4 1593/4885NPBWR1 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.